Almirall, S.A. (ALMRY) Q2 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good day, and thank you for standing by. Welcome to the twenty twenty six First Half Earnings Call of Almirall. At this time, all participants are in a listen only mode. After the speakers' presentation, there will be a question and answer Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Pablo de Vason, Head of Investor Relations. Please go ahead. Thank you very much, Sharon, and good morning, everyone. Thank you for joining us for today's quarterly earnings update and review of Almirall first half year financial results of 2026. As always, the slides we are using today are shared in the Investors section of our website at almirall.com. Please move to Slide number two. Let me remind you that the information presented in this call contains forward looking statements, which involve known and unknown risks, uncertainties and other factors that may cause actual results to materially differ from what we are sharing today. Please move to Slide number three. Presenting today are Carlos Gallardo, Chairman and Chief Executive Officer John Karai, Chief Financial Officer and Carl Sigabara, Chief Scientific Officer. Karl will start with the business highlights of the first half of twenty twenty six, followed by an update on biologics and the key growth drivers of our medical dermatology portfolio. Karl will provide you with an update on the pipeline and R and D programs. And then John will go through the financial before Carlos concludes the presentation and we open for questions. I will hand over to Carlos Gallardo, our Chairman and CEO. Please move to Slide number five. Thank you, Pablo, and good morning to everyone in the world. Almirall delivered a steady first half of twenty twenty six, broadly ...